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CHINA'S HEALTHCARE REFORM: HOW PATENT LAWS AND
GENERIC DRUGS CAN BENEFIT CHINA'S PUBLIC HEALTH
Patrick Russo
CHINA'S HEALTHCARE ISSUES
Imagine a place where a sick or disabled child is quickly disowned by his parents
and handed over to the government. Imagine a medical care system that forces a father to
abandon his three-month-old daughter in front of an orphanage at six in the morning.
Imagine a government that purposely establishes drop-off centers for medically adverse
children because their parents are financially unable to care for them. Surely, no such place
could exist, right? It just so happens that the world's most populous country, and the largest
economy, is currently facing this dilemma.'
Late afternoon in the Sichuan province of China, a young, 21-year-old father holds
his newborn son in one arm, and all the infant's cloths and belongings in a bag in the other
arm. 2 The child has a rare medical condition that causes fluids to aggregate around the brain,
causing severe brain damage, and possibly leading to death. Due to China's healthcare
system, this father is unable to afford the proper medical care for the child, and now attempts
to leave his son at a newly opened "baby-hatch" in an orphanage. 4 A "baby-hatch" is an
additional section affixed to an orphanage, where financially strained parents can abandon
their children suffering from unique disorders.5 Once the children are left, the government
6
funded orphanages then presumably provides care for these abandoned babies.
Since the opening of the first "baby-hatch" in China in 2011, more than 30

Patent Agent and Candidate for J.D., Hofstra University School of Law, 2016.
Population, total, THE WORLD BANK, http://data.worldbank.org/indicator/SP.POP.TOTL (last visited Oct.
08, 2015); China's Population Set to Peak at 1.4 Billion Around 2026: Census Bureau Projects India to
Become
Most
Populous Country in
2025,
U.S.
CENSUS
BUREAU
(Dec.
15,
2009),
http://www.census.gov/newsroom/releases/archives/internationalpopulation/cb9-191. html (discussing the
population growth in China and how India will be surpassing China has the most populous country in about a
decade); CARL J. DAHLMAN & JEAN-ERIC AUBERT, CHINA AND THE KNOWLEDGE ECONOMY: SEIZING THE 21'

CENTURY

(The

World

Bank

Institute

Publ'n

2001),

http://info.worldbank.org/etools/docs/library/137742/ChinaKE.pdf; see generally ANGUS MADDISON, CHINESE
ECONOMIC PERFORMANCE IN THE LONG RUN (OECD Dev. Ctr., 2d ed. 2007) (discussing the economic

emergence of China); CNN Staff, CHINA: Sick Children Being Abandoned Because Parents Can 't Afford
Medical Care, WDAY NEWS (June 30, 2014, 11:30 AM), http://www.wday.com/content/china-sick-childrenbeing-abandoned-because-parents-cant-afford-medical-care.
2 CNN Staff, supra note 1.
3 Id.
4

Connie

Young, China 'Baby Hatch' Inundated with Abandoned, Disabled Children, CNN (June 30, 2014,

7:56 AM), http://www.cnn.com/2014/06/30/world/asia/china-baby-hatches-jinan/;

Seth Doane, A Look at

China's

27,

"Baby

Hatches" for

Unwanted Infants,

CBS

NEWS

(June

2014,

7:23

PM),

http://www.cbsnews.com/news/a-look-at-chinas-baby-hatches-for-unwanted-infants/;
Jing Gao, Chinese City
Sets Up Baby Hatch to Tackle Child Abandonment, MINISTRY OF TOFU (Mar. 6, 2012),

http://www.ministryoftofu.com/2012/03/chinese-city-sets-up-baby-hatch-to-tackle-child-abandonment/.
5 Young, supra note 4.
6 Id.
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additional "baby-hatches" have been launched across the country. According to the Chinese
government, the amount of orphans in China is just north of 700,000.8 Studies show,
however, that the number is more likely in the millions, especially with the emergence of the
hatches. 9 The majority of children left at these "baby-hatches" have disabilities or suffer
from medical conditions (mostly rare medical disorders). o Staggeringly, China is now on the
top 15 list of countries with the highest under-5 mortality rate, according to UNICEF, and this
number has been steadily increasing since 1990."
Many of these issues are negative effects of the poor healthcare system in China.1
Over the past two decades, several major trends stand out as a result of the declining
healthcare market. " One is the overall price increase in medical care, especially for a major
illness or injury, and the increase in public "out-of-pocket" spending that coincides with
this.1 4 Since the 1970s, public spending on healthcare increased from 20% to 60%. " The
quality of healthcare has also been inconsistent depending on location. 16 For instance,
medical care and hospital quality are significantly better in urban areas than in the rural
Only 20% of China's health services are in rural areas. This has led to civil
countryside.
unrest and instability as the citizens fight for better health services. 19 As part of the Healthy
China 2020 program, the Chinese government is currently initiating a two-tiered reform of
medical care and the health care system. 2 0 The government seeks to establish universal
coverage of basic medical insurance, an essential drug system for increased generic drug use,
health care infrastructure upgrades, greater health care equality between the urban and rural
parts of China, and the facilitation of private investment for hospitals. 2 This note will focus
on China's drug system, and propose a method for improving access and affordability of

Id.
9 Id.
10 Id. (naming some medical conditions like congenital heart diseases, brain diseases, tumors, and breathing
complications).
" China:
Statistics,
UNICEF:
UNITED
NATION'S
CHILDREN
FUND,
http://www.unicef.org/infobycountry/chinastatistics.html (Last visited November 13, 2014); Mortality Rate,
Infant (Per 1,000 Live Births), THE WORLD BANK: WORKING FOR A WORLD FREE OF POVERTY,
http://data.worldbank.org/indicator/SP.DYN.IMRT.IN (Last visited November 13, 2014).
12 See generally OFFICE OF WORLD HEALTH ORG. REPRESENTATIVE IN CHINA AND Soc. DEv. DEP'T OF
CHINA STATE COUNCIL DEv. RESEARCH CTR., China: Health, Poverty and Economic Development (2005),

http://www.who.int/macrohealth/action/CMHChina.pdf.
" Benjamin L. Liebman, Essay: Malpractice Mobs: Medical Dispute Resolution in China, 113 COLUM. L.
REv. 181, 189-92 (2013).
I4 Id.

"s Id. at 188.
16 Thomas R. McLean, Article: International Law, Telemedicine & Health Insurance: China as a Case Study,
32 Am. J. L. and Med. 7, 17 (2006).
17 Id.

1s Id.
'9
20

Liebman, supra note 13, at 243.
See Ian Lewis, A Different Kind ofHospitality Opportunity in China, LAW360 (Oct. 23 2014).

21 SWEDISH AGENCY FOR GROWTH POL'Y ANALYSIS,
QUALITY
IMPROVEMENTS

CHINA'S HEALTHCARE SYSTEM: OVERVIEW AND
(2013),
available
at

http://www.tillvaxtanalys.se/download/I8.5f097bc113eacc3d6d513e/ 136903362175 1/direct response_2013_0
3.pdf; David Blumenthal & William Hsiao, Privatization and its Discontents: The Evolving Chinese Health
Care System, N ENGL J. MED (2005), http://www.nejm.org/doi/fulW 10. 1056/NEJMhprO51133.
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pharmaceuticals. In the 1980s, the U.S. government implemented the Hatch-Waxman Act
and the Orphan Drug Act, which helped reshape the country's drug system.2 2 The former
regulated and encouraged the manufacturing of generic drugs, and the latter sought to
facilitate research and development of orphan drugs through various incentives. 2 3 Both acts
have improved U.S. public health while protecting patent rights, and they continue to be
effective three decades later.2 4 This note proposes that the Chinese government adopt the
guidelines presented in both the Hatch-Waxman Act and the Orphan Drug Act. Following the
general protocol of these federal laws would fill the gap in a drug system that fails to address
these issues, and help establish a foundation for the drug system sought by the government's
current healthcare reform.
In Part I, this note first discusses the importance of having both patent protected
pharmaceuticals and access to generic drugs, and how this relationship between the patent
market and big pharma industry affects public health. Part II then examines global efforts to
combat this issue of protecting and developing both public health and intellectual property
rights, such as compulsory licenses and the Doha Declaration.
The United States'
involvement in these world efforts is discussed in Part III, along with an overview of the U.S.
patent system, the Hatch-Waxman Act, and the Orphan Drug Act. Part IV provides a
comparison between the U.S. and Chinese patent systems, and examines China's healthcare
system reform and how the two U.S. laws could be implemented.
I. MEDICINAL DRUG PATENTS AND THE PHARMA INDUSTRY
There is an ongoing controversy between two giant players in the world economy.
The intertwining relationship between the patent market and the pharmaceutical industry is
25
complicated, and is the cause of much debate.
It affects individual nations, as well as the
international landscape; private companies, as well as the public commercial sector; and the
government, as well as public welfare. 2 6 When patents are issued to protect prescription
drugs, private pharmaceutical companies usually own the rights to produce and sell these
drugs.2 7 This causes drastic price increases in medication, creating a financial barrier for
suffering people who cannot afford medicine. 2 8 The availability of patent protected
pharmaceuticals in developing and industrialized countries has become an issue, since many
patients are unable to afford the proper medicine from the pharmaceutical companies. 29
A major dilemma that demonstrated the importance of access to drugs, but also

22 Judy Vale, Article, Expanding Expanded Access: How the Food and Drug Administration Can Achieve

Better Access to Experimental Drugs for Seriously Ill Patients, 96 GEo L. J. 2143, 2166-67 (2008).
23 Id. at 2167.
24 See generally id.
2s Pharmaceutical

Pricing:
The
New
Drugs
War,
THE
ECONOMIST
(Jan.
4,
2014),
http://www.economist.com/news/leaders/21592619-patents-drugs-are-interests-sick-well-industry-protectionshould-not [hereinafter Pharmaceutical Pricing].
26 Id.

27 The

Controversy

About Patents for Pharmaceuticals, FEDCIRC.US
http://www.fedcirc.us/the-controversy-about-patents-for-pharmaceuticals.php,
2014) [hereinafter Controversy About Patents for Pharmaceuticals].
28

PATENT
(Last

LAW

visited

INFORMATION,
November

13,

H. David Banta, Worldwide Interest in Global Access to Drugs, 285 J. AM. MED. 22, 2844-46 (2001)

[hereinafter Banta].
29 Liebman, supra note 13, at 3.
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reiterated the significance of intellectual property rights, was the HIV crisis in South Africa,
which erupted in 1998.30 At the time, South Africa became "the country with the highest
absolute number of people living with HIV/AIDS." 3 ' According to the South African
Department of Health, since the average annual income in the country was $2,600 and the
cost of medicine for HIV was about $1,000 a month, most affected people could not afford
the proper medication.32 The South African legislature passed a statutory amendment that
allowed the import and distribution of patented pharmaceuticals to combat the pandemic.
The pharmaceutical companies argued that the parallel imports violated patent holders' rights
to their patents, while South Africa, and the public, pleaded the need for affordable medical
care. 34
A. Importance of Patents for Pharmaceuticals
A patent is the grant of exclusive rights by a government to the patent owner to
35
exclude others from commercially using, making, or selling the patent owner's invention.
The invention must be novel, useful, and non-obvious in order to be granted a patent, and it
could not have been sold, used, or published about before the inventor files for patent
protection.
In order to gain exclusive patent rights, the inventor or owner must file an
application with the government's patent office, which in the U.S. is the United States Patent
and Trademark Office (USPTO). 37 Once an inventor is granted a patent, the invention is
under patent protection for twenty years from the date of filing.
There are many benefits that come from patent protection, including both economic
and societal effects.3 9 The main purpose of the patent system is to promote innovation while
also protecting individuals' intellectual property. 40 Essentially being granted a monopoly
30 PharmaceuticalPricing, supranote 25.

William W. Fisher & Cyrill P. Rigamonti, The South Africa AIDS Controversy: A Case Law Study in Patent
Law
and Policy,
HARV.
L.
SCH.:
THE
L.
AND
Bus.
PAT.
(Feb.
10, 2005),
http://cyber.law.harvard.edu/people/tfisher/South%20Africa.pdf; Steven Casper, Between Free Market and
Human Right: Government Policy, the PharmaceuticalIndustry and the HIV/AIDS Crisis, KECK GRADUATE
INST., CLAREMONT C. (Oct. 2011), http://pacs.einaudi.comell.edu/system/files/Casper-PKfestV2.pdf; See
generally Lissett Ferreira, Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations of
MultinationalPharmaceuticalCorporations,71 FORDHAM L. REv. 3, 1132-80 (2002).
32 Fisher & Rigamonti, supra note 3 1.
3 Id.
31

34 Id.

Jehangir Choksi, Bereskin & Parr, The Benefits and Costs of Patent Protection, IEEE CAN. (1999),
http://www.ieee.calcanrev/canrev32/choksi.pdf; Chapter 2: Fields of Intellectual Property Protection, WIPO
(2004), http://www.wipo.int/export/sites/www/about-ip/en/iprm/pdf/ch2.pdf;
35 U.S.C. §102 (1952).
36 Choksi et al., supra note 35.
3 Id.
3s

38 United

States Patent and Trademark Office, 2701 Patent Term, MANUAL OF PATENTING EXAMINING

PROCEDURE (91h ed. Rev. 11.2013, Mar. 2014).
39 James Yang, Benefits of Patent Protection, OC PATENT LAWYER, http://ocpatentlawyer.com/benefits-of-

patent-protection/ (last visited Nov. 13, 2014) [hereinafter Yang]; Kristina Lybecker, Promoting Innovation:
The

Economics

of

Incentives,

IP

WATCHDOG

(July

21,

2014),

http://www.ipwatchdog.com/2014/07/21/promoting-innovation-the-economics-of-incentives/id=50428/;
PharmaceuticalPricing, supra note 25.
40

Lybecker, supranote 39.
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over an invention, being rewarded exclusive rights to exclude market competitors, serves as
incentive for people to study new technology and to continue with research and
development. 4 1 Patent protection prevents the theft of inventions and new ideas from those
who initially conceived of the innovations. 42 Instead, it compensates those who have spent
time and money researching, developing, and reducing their inventions to practice.4 3
Firstly, besides compensation for inventors' hard work, the economic and financial
benefits for the patent owner include higher profit margins and expanded market share.4 The
increased profits are a result of higher prices for the invented product. 45 These prices are to
recover for the large investments spent on research and development, as well as the high
demand and sole responsibility of supply by the patent owners.4 6 The need for the invented
product in other states, or even countries, can lead the patent owner to license the product to
companies abroad, therefore expanding the market share for the invention.47
Next, the community can greatly benefit from patents as well, because the products
are marketed, sold, and used by society.4 8 Specifically with pharmaceuticals, patent
protection encourages inventors to continue their research and development, which in turn
creates stronger, improved medicine. 4 9 These pharmaceuticals created by private pharma
companies carry moral weight and create a public service. 50 People have a right to quality
5
health and medical care, and are more productive members of society when healthy.
Medicine prevents diseases and the spread of epidemics, contributing to an effective and
functioning society.52
B. Importance of Generic Drugs
A generic drug is a drug product that is deemed identical to the original, patented
drug in "dosage form, safety, strength, route of administration, quality, performance
characteristics and intended use."5 When a patent term expires for a specific pharmaceutical,
generic versions of that drug can be produced and sold. 54 Typically, when generic drugs are
used or sold pre-patent term expiration, an infringement action is brought against the
'

Id.

42 Yang, supra note 39.
43 Banta, supra note 28, at 2845.
'

Yang, supra note 39.

4S Id.
46

47

id.
id.

48 PharmaceuticalPricing,supra note 25

49 Jorg

Schaaber, Misguided Research, DEVELOPMENT AND COOPERATION (November 1, 2010),
http://www.dandc.eu/en/article/why-patents-often-stand-way-health-care
(mentioning how revenue from
patents intrigues inventors and promotes development for certain disease treatments) [hereinafter Schaaber].
5o PharmaceuticalPricing,supra note 25.
5' Id.
52 Id.

" Understanding Generic Drugs, U.S. FOOD AND DRUG ADMIN. (last updated Oct. 23, 2014),
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGeneric
Drugs/.
5

Drugs: Facts About Generic Drugs, U.S. FOOD AND DRUG ADMINISTRATION (last updated Sept. 19, 2012),
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafelyUnderstandingGeneric

Drugs/ucm167991 .htm [hereinafter Facts About Generic Drugs].
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infringers. There are, however, unique exceptions to this problem that will be addressed in a
later section. Competition among drug production companies increases without patent
protection, consequently reducing the price of the generic drugs."s The companies also do not
need to pay for the clinical trials, marketing, and advertising that would be needed for new,
brand named drugs.5 6 This creates a more affordable version of the expensive medicine."
Generic drugs, on average, cost about 80-85% less than their brand name counterparts.5 In
one year, generic drugs can save U.S. consumers about three billion dollars a week.59
Many people are skeptical of generic drugs, and feel that they do not provide the
same positive medical effects as the brand named versions.6o The U.S. Food and Drug
Administration has evaluated evidence from studies comparing particular brand named drugs
with their generic counterparts, i.e. cardiovascular medicine, which showed no medically
significant variability. 6 ' The FDA also ensures that the generic product will meet the same
quality standards as the brand name drug, and will meet the same testing and manufacturing
specifications as well. 62
One of the most common, and most important, drugs is Ibuprofen. 63 This is an antiinflammatory that helps relieve pain and lower fevers, originally patented in 1961.64 Once the
patent expired, pharmaceutical companies were able to produce and sell Ibuprofen
independently. Since then, lbuprofen has become quite popular, sold under different, wellknown trade names like Advil, Motrin, and Nurofen. 65 Another similar pain relief medicine
is acetaminophen, or paracetamol, which is an anti-inflammatory that is used to treat arthritis,
66
Like the patent for Ibuprofen, the patent rights
as well as prevent heart attacks and strokes.
for acetaminophen have long expired, thus there are a wide variety of trade names selling the
generic version of this drug.67 Common generic Acetaminophen trade names in the United
States include Aspirin, Tylenol, and Panadol." Millions of people take these drugs, many of
" Id.
5 Id.
5 Drugs: What Are Generic Drugs, U.S. FOOD AND DRUG ADMINISTRATION (last updated May 12, 2009),
http://www.fda.gov/Drugs/ResourcesForYoulConsumers/BuyingUsingMedicineSafely/UnderstandingGeneric
Drugs/ucml144456.htm.
s Savings: $1 Trillion Over Ten Years - Generic Drug Savings in the U.S. Fourth Annual Edition 2012,
GENERIC

PHARMACEUTICAL

AssOCIATION

(2012),

http://www.gphaonline.org/media/cms/IMSStudyAug20l2WEB.pdf.
9 Id.
6 Facts About Generic Drugs, supra note 54.
61 Aaron
S. Kesselheim, et al., Clinical Equivalence of Generic and Brand-Name Drugs Used in
Cardiovascular Disease: A Systematic Review and Meta-analysis, 300 J. AM. MED. 21, 2514-26 (2008).
62 Facts About Generic Drugs, supra note 54.
63 See generally, World Health Org. [WHO], WHO Model List
of Essential Medicines: 18'h List (Apr. 2013),
http://apps.who.int/iris/bitstream/10665/93142/1/EML_1 8eng.pdf?ua=1.
64 Gayle M. Halford, Marie Lordkipanidz & Steve P. Watson, 5 0'h Anniversary of the Discovery of Ibuprofen:
An Interview with Dr. Stewart Adams, 23 PLATELETS 6, 415-22 (2012).
65 Ibuprofen
(By
Mouth),
PRE
MED
HEALTH
(July
1,
2015),
http://www.ncbi.nlm.nih.gov/pubmedhealthlPMHT0010648/?report-details.
6
Paracetamol, DRUGS.COM, http://www.drugs.com/paracetamol.html (last visited Nov. 13, 2014) [hereinafter
Paracetamol].
67 Karan B. Thakkar & Gauri Billa, The Concept of Generic Drugs and Patented Drugs vs. Brand Name
Drugs and Non-proprietary (Generic) Name Drugs, PUBMED- U.S. NAT'L LIBRARY OF MED. (Sept. 12, 2013),
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770914/.
68

Paracetamol, supra note 66.
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which use the drugs on a daily basis, so it is easy to see the importance of accessibility to
pharmaceuticals.' 9
II. WORLD EFFORTS TO INCREASE ACCESS TO ESSENTIAL MEDICINE
A. International Organizations
Efforts to regulate and improve international trade have long been part of the world
economy.70 After World War II, the General Agreement on Tariffs and Trade (GATT) was
initiated by the United Nations as an initial basis to create mutually advantageous trade
opportunities for its member states." The goals of the GATT were to lower trade tariffs and
barriers, and to promote trade relations between nations. 7 2 It set the foundation for a longterm, multilateral, international trade system, however after almost half a century, the system
needed a makeover.13 A more successful and efficient organization was established in 1995,
the World Trade Organization (WTO), replacing the GATT.74 The implementation of the
WTO established the world's largest international trade agreement with the current
involvement of 160 member states. 7 ' The World Trade Organization oversees all aspects of
international trade, including: goods, services, intellectual property, negotiation, and dispute
resolution.7 6 Ensuring fair market competition is a cornerstone of the WTO, the WTO
implements five main principles: non-discrimination, reciprocity, binding and enforceable
commitments, transparency, and safety valves. 7 7 The last of these, safety valves, aims to
protect and develop the public health, and concerns the proper use of patent protection.
The Agreement on Trade-Related Aspects of Intellectual Property Rights, also
known as TRIPS, is an international agreement founded by GATT in 1994 and currently
administered by the WTO. 79 This agreement is a staple of the international intellectual
property trade system, setting the standards for intellectual property regulation for WTO
members.so The goal was to set guidelines for intellectual property protection, like

69

id.
Modest Trade Recovery to Continue in 2015 and 2016 Following Three Years of Weak Expansion, WORLD
TRADE ORGANIZATION (April 14, 2015), https://www.wto.org/english/news e/presl5 e/pr739_e.htm.
7' Timeline:
World
Trade
Organization,
BBC
(Feb.
2,
2012,
7:31
PM),
http://news.bbc.co.uk/2/hi/europe/countryjprofiles/2430089.stm.
72 Robert W. Staiger, The Economics of GATT, THE NAT'L BUREAU OF ECONOMIC RESEARCH,
http://www.nber.org/reporter/spring99/staiger.html (last updated Jan. 7, 2015).
n The
GA TT
Years:
From
Havana
to
Marrakesh,
WTO,
http://www.wto.org/english/thewtoe/whatis-e/tif e/fact4_e.htm (last visited Jan. 6, 2015).
74 BERNARD M. HOEKMAN ET AL., WORLD BANK, DEVELOPMENT, TRADE, AND THE WTO: A HANDBOOK 41
(2002) [hereinafter Hoekman].
7 Members
and Observers, WORLD
TRADE
ORG.
(Last
visited
January
6,
2(15),
http://www.wto.org/english/thewtoe/whatis-e/tif e/org6_e.htm.
76 Hockman, supra note 74.
n Principles of
the
Trading
System,
WTO
(last
visited
January
6,
2015),
http://www.wto.org/english/thewtoe/whatis-e/tife/fact2_e.htm#seebox.
70 id.
' WTO TRIPS Implementation, INT'L INTELLECTUAL PROP. ALLIANCE, http://www.iipa.com/trips.html. (last
visited Jan. 6, 2015).
70

80 Id.
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patentability requirements and the length of patent terms, during international trade. TRIPS,
however, has received heavy criticism from developing countries because of its heavy
influence and protection of patents, which has negative effects on access to medicine.8 2 The
implementation of TRIPS causes not only increases in drug prices, but also decreases in
research and development of treatments for rare diseases and diseases that predominantly
affect developing countries.8 3 This is a huge dilemma, especially since more than threefourths of the world population lives in developing countries, yet they account for less than
10% of the pharmaceutical market.84
The World Trade Organization, along with the help of the World Health
Organization (WHO), took drastic steps in initiating agendas aimed at alleviating this issue.ss
The outbreak of HIV/AIDS in both Africa and Brazil in the 1990s caused the necessity of
86
medicine in order to combat the disease and help the ailing.
The patent protection afforded
to pharmaceuticals spurred an outcry to circumvent the patents in order to provide easier
access to medicine.
This caused a shift in the attitudes about patent protection among
international agencies such as the WTO and WHO. 8 These organizations placed an emphasis
on promoting public health over trade interests, which was controversial in the commercial
pharmaceutical industry.9
B. Compulsory Licenses and NGOs
An example applying this movement to promote public health over commercial
interests was the Brazilian AIDS Programme, established by the Brazilian government.90
Like South Africa, Brazil was suffering from a widespread HIV/AIDS epidemic during the
mid-1990s and needed access to medicine. 9 ' Half a billion people in Brazil are infected with
HIV, but with the support of non-governmental organizations (NGOs), like Doctors Without
Borders, Brazil was able to reduce its AIDS-related mortality rate by 50% in just three years
and save almost half a billion dollars in treatment costs.92 Two major reasons the Programme
was so successful were the production of medicine locally and the implementation of
compulsory licenses. 9 3 Compulsory licensing in this context is when the government allows

81

Id.

82 Ellen F.M. 'T Hoen, TRIPS, PharmaceuticalPatentsand Access to Essential Medicines: Seattle, Doha and

Beyond, 3 CHI. J. INT'L L. 27, 27 (2002) [hereinafter Hoen].
83 Id.

8 Id. at 28.
8s

Id. at 35.

86

Id. at 32-33.

87 Angela J. Anderson, Global Pharmaceutical Patent Law in Developing Countries
- Amending TRIPS to

Promote
Access
for
All,
BEPRESS
LEGAL
REPOSITORY
http://law.bepress.com/cgi/viewcontent.cgi?article=5237&context-expresso.
88

(Mar.

9,

2006),

See Id.

89 Hoen, supra note 82, at 35-36.

9 Id. at 32.
91 Id.

Id. at 44-45.
9 Id. at 32.
92
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for the production of a patented product without the consent of the patent owner. 94 This is
one of the flexibility propositions provided under the TRIPs Agreement, and was enacted into
Brazilian patent law. 95 Under TRIPs, there are specific situations that allow for the use of
compulsory licenses in order to circumvent strict patent restrictions. 9 6 Several of these
include: inventions funded by the government; lack of research and development over a
certain period of time in the territory of a patent; where the refusal of a license leads to the
inability to exploit the important use of a patent, national emergency, or extreme urgency; and
cases of non-public commercial use. 9 7 These last two listed situations where the factors used
to justify implementation during the HIV/A[DS crises in Brazil and South Africa." The
generic copies of the drugs during periods of compulsory licensing are mainly for domestic
use, not for export, which is why Brazil was so successful in the local production and
distribution of medicine. 99
Doctors Without Borders is part of a larger NGO, M6decins Sans Frontibres, which
has medical programs in 70 countries and aims to promote the access and affordability of
medicine to anyone who needs.'oo This relief organization has collaborated with other NGOs
and activist groups, such as Oxfam, Voluntary Service Overseas, and Action Aid, in order to
advocate for affordable healthcare in developing nations.'O' These collaborations, along with
participation of national governments, were the reasons for success in countering the negative
effects of the TRIPs agreement, and battling diseases like HIV/AIDS, Ebola, and tuberculosis
in developing countries. 0 2 Besides Brazil and South Africa, other countries that have been
negatively affected by TRIPs, where NGOs continue to work, include Kenya, Guatemala, and
Thailand - which has over 600,000 people infected with HIV/AIDS, but now has access to
medicine 25 times cheaper than the brand name equivalent. 103 Drawing attention to the
disparity between patent prices and the affordability of drugs continues to be a focus of these
NGOs.'4
C. The Doha Declaration
The WHO's initiative to put public health before intellectual property rights was
highly controversial. os Western countries like the United States and a number of European

4 Compulsory Licensing of Pharmaceuticals and TRIPS, WORLD TRADE ORG. (Sept. 2006),
http://www.wto.org/english/tratope/tripse/public-health-faq e.htm [hereinafter Compulsory Licensing].
95 Hoen, supra note 81, at 32.
96 URUGUAY ROUND AGREEMENT. TRIPS, Part 1I- Standards Concerning the Availability, Scope and Use
TRADE ORG., http://www.wto.org/english/docs-e/legal-e/27-

of Intellectual Property Rights, WORLD

trips 04c e.htm (last visited Oct. 8, 2015).
9 Id.
9 Hoen, supra note 82, at 32.
9 Compulsory Licensing, supra note 94.

100

About MSF, MEDECINS SANS FRONTIERES, http://www.msf.org/about-msf. (last visited Oct. 8, 2015).

10' Nathan Ford, Patents, Access to Medicines and the Role of Non-Governmental Organizations, I J. GENERIC

MED. 137, 139 (2004) [hereinafter Ford] (discussing the importance of the partnerships between NGO's like
Medecins Sans Frontieres and other activist groups).
102

Id.

'03 Id. at 141.

I0
105

Id. at 144.
Hoen, supra note 82, at 48.
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nations opposed this solution to the AIDS crisis and urged for the protection of patent
rights. o0 The Directorate General of Trade for the European Commission even stated, "[n]o
priority should be given to health over intellectual property considerations."', 0 7 Other
organizations like UNAIDS, the World Bank, and the United Nations voiced their opinions on
After much debate, the WTO decided to organize a
the need for access to medicine. '
special council to address access to pharmaceuticals and public health at the Doha Conference
in 2001.109
In Doha, Qatar, about twenty developing countries joined together and presented a
text proposal for clarifications of the TRIPs Agreement and related topics, such as
compulsory licensing."o They wanted industrialized countries to stop implementing trade
pressures in order to protect their pharmaceutical industries.1" The opposing side, consisting
of more developed countries like the United States, Japan, Switzerland, Australia, and
Canada, proposed an alternate draft that focused more on intellectual property rights and
protection for research and development.112 This side, along with the European Union,
argued that intellectual property contributes to public health, and that inhibiting patent
protection in favor of compulsory licensing and parallel imports would be counterproductive
to the improvement of public health." 3 Patent owners and big pharma companies would lose
both money on their pharmaceuticals, and the incentive to continue research and development
for improvements. 114 This, in turn, would lead to less advanced pharmaceuticals and a lack of
sufficient medicine accessible to the public." 5
After several days of negotiation, a compromise was reached that would reaffirm
much of the flexibility of the TRIPs Agreement, and make clear the boundaries between
patent rights and access to medicine.' 16 This compromise, the Doha Declaration, made clear
that the TRIPs Agreement would not prevent any member state from protecting public
health."' Each member of the agreement is allowed to create its own regime for "exhaustion
of intellectual property rights," which means they are free to decide what constitutes a
national emergency or extreme urgency in order to grant compulsory licenses to circumvent
patent rights." 8 Member countries decide the grounds upon which compulsory licenses can

106

Id.

0o

Id. at 48.

os Id. at 49.
['

Id.

'10 CARLOS M. CORREA, WHO, IMPLICATIONS OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND
PUBLIC HEALTH, at 3 (2002).

". Ford, supra note 101, at 143.
112 Hoen, supra note 82, at 51.
113 Id.
114

Jon

Matthews, Renewing Healthy Competition: Compulsory Licenses and Why Abuses of the TRIPS Article
31 StandardsAre Most Damaging to the United States Healthcare Industry, 4 J. BUS. ENTREPRENEURSHIP & L.
118, 122 (2010).
" Id.
116 Hoen, supra note 82, at 52.
" Vanessa Bradford Kerry & Kelley Lee, TRIPS, the Doha Declarationand Paragraph6 Decision: What are
the Remaining Steps for Protecting Access to Medicines, 3 GLOBALIZATION AND HEALTH 1, 2 (2007)

(discussing the uncertainty of where the Doha clarifications about TRIPS would lead, and the undermining of
developing countries' abilities to manufacture pharmaceuticals).

11 Declaration
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and

Public

Health,
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(Nov.

20,

2001),
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be granted within their borders, and what defines a national emergency, for instance
epidemics like HIV/AIDS, tuberculosis, and malaria." 9 Big pharma industries and
organizations like the United States Trade Representation protested the declaration and
argued that it would have devastating effects on research and development.120 TRIPs still
provides protection for patent owners, however, it allows for developing countries to also
protect their citizens, promote public health, and increase access to medicine. 121 The current
status of the Doha Declaration remains mostly unchanged, but a new amendment has recently
been proposed. 2 2 The proposal would allow for WTO member countries to export generic
versions of drugs to countries that do not have the capability or capacity to manufacture for
themselves. 2 31In order for the amendment to be formally ratified, two-thirds of the 153 WTO
members must agree.124 As of now, only 53 members have accepted the agreement, and the
deadline for acceptance has been extended to the end of December, 2016.'125
III. U.S. PHARMACEUTICAL PATENT POLICIES
A. U.S. Guidelines in Accordance with WTO Guidelines
United States patent law is authorized and protected by Article One of the U.S.
Constitution, and gives the patent holder the right to prevent others from making, selling, and
using the invention during the patent term.126 The term typically lasts for twenty years from
the time of filing the patent application with the United States Patent and Trademark Office in
Virginia.1 2 7 The U.S. government has strongly defended patent rights, and all intellectual
property rights, since the making of the Constitution and values the importance that patent
protection contributes to society. 12 At the same time, the U.S. believes in protecting and
promoting public health.129 Thus, as a member state of the World Trade Organization, the
U.S. adopted the 2001 Doha Declaration of the TRIPS Agreement and Public Health. 30
Aside from following international organization guidelines, the U.S. has long sought
to promote and advance public health and safety, not only abroad through the WTO and
WHO, but also domestically. '' This is evident through the establishment of government
offices, such as the Department of Health and Human Services, and the Public Health Service

11 Id.
120 Hoen, supra note 82, at 56.
121 Overview:
The
TRIPS
Agreement,
WTO
(last
visited
Jan.
6,
2015),
http://www.wto.org/english/tratop e/trips-e/intel2_e.htm.
122 Members Accepting Amendment of the TRIPS Agreement, WTO (last updated
Sept. 10, 2014),

http://www.wto.org/english/tratop e/trips e/amendment-e.htm [hereinafter Members Accepting].
123 Members OK Amendment to Make Health Flexibility Permanent, WTO
(Dec.

6,

2005),

http://www.wto.org/english/news-e/pres05_e/pr426_e.htm.
124 Members Accepting, supra note 122.
125

Id.

126 U.S. CONsT. art. I, § 8, cl. 8.
127 Chapter2, supra note 35.
128

See generally, 35 U.S.C. § 154 (2013).

129 See generally, LAWRENCE 0. GOsTIN, Public Health Law: Power, Duty, Restraint 43 (2d ed. 2008).
130 Hoen, supra note 82, at 51.
'

Global Health, OFFICE OF DISEASE PREVENTION AND HEALTH PROMOTION (last visited December 1, 2015),

http://www.healthypeople.gov/2020/topics-objectives/topic/global-health.
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Act of 1944 that restructured the United States Public Health Service, which was founded in
1798.132 The Department of Health was established with the goal of "improving the health,
safety, and well-being of America," and originally included the now separate Department of
Education.' 3 3 It includes sub-departments and agencies, the primary division being the Public
Health Service, which consists of most of these sub-compartments.134 They include, but are
not limited to, the Office of the Surgeon General, Agency for Healthcare Research and
Quality, Centers for Disease Control and Prevention, Food and Drug Administration, Health
Resources and Services Administration, and National Institutes for Health.135 Across these
divisions, the Department of Health has issued many programs to further implement its goal
of promoting public health; these programs include health and social science research,
preventing disease and providing immunization, Medicare and Medicaid, health information
technology, financial assistance, and medical preparedness for emergencies. 136 Altogether,
the Department of Health and Human Services and its branches maintain an established
network for developing and improving the nation's public health and well-being.
On top of protecting public health, the U.S. government also understands the need to
protect intellectual property, and aims to establish a balance between the two ideas.' As a
member state of the WTO and of the Doha Declaration, the United States agreed to the
flexibility on the TRIPS Agreement for developing countries, but the U.S. also wants to
Before the
prevent patent holders and the pharmaceutical business from being exploited.
Doha Declaration, and even before the TRIPS Agreement, the U.S. has aimed to make sure its
citizens' intellectual property rights are adequately and effectively protected abroad as well as
at home.
Section 301 of the Trade Act of 1974 does just that. 40 The Office of the United
States Trade Representative (USTR), a government agency that conducts and develops trade
policy and negotiations, provides an annual report identifying those countries that inhibit the
intellectual property rights of U.S. citizens and companies.141 This report, known as the
Special 301 Report, seeks trade barriers to U.S. products and creates a Watch List of countries
that do not adhere to the USTR policies of "fair and equitable market access to United States

132 About HHS, U.S. DEP'T OF HEALTH AND HUMAN SERv., http://www.hhs.gov/about/
(last visited Jan. 27,

2015); Public Health Service Act of 1944, 59 Public Health Reports 916 (July 14, 1944).
"3

Health Information Privacy, U.S. DEP'T OF HEALTH & HUM. SERV. http://www.hhs.gov/ocr/privacy/ (last

visited Jan. 27, 2015).
134 HHS

Organizational
Chart,
U.S.
DEP'T
OF
http://www.hhs.gov/about/orgchart/ (last visited Jan. 27, 2015).
135 Id.
36 HHS

Programs

and

Services,

U.S.

DEP'T

HEALTH

OF

HEALTH

AND

&

HUMAN

SERV.,

HUMAN

SERV.,

http://www.hhs.gov/about/programs/index.html (last visited Jan. 27, 2015).
13" Victoria E. Hopkins, Analysis of InternationalPatent Protection and Global Public Health, 17 PRINCETON

J. OF PUB. INT'L AFF. 83, 84 (2006).
38 Hoen, supra note 82, at 51.

1' Letter from Steve Metalitz, Michael Schlesinger, Eric Schwartz, Amanda Wilson Denton, Counsel for Int'l
Intellectual Prop. Alliance, to Susan F. Wilson, Dir. for Intellectual Prop. & Innovation, U.S. Trade
Representative (Feb. 7, 2014).
140 19 U.S.C. § 2411 (2012); 19 U.S.C. § 2242 (2012).
141 Mission of the USTR, OFFICE OF THE U.S. TRADE REPRESENTATIVE, https://ustr.gov/aboutus/about-ustr (last visited Jan. 27, 2015).
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persons that rely upon intellectual property rights." 4 2 Priority Foreign Countries on this list
are those that "have the most onerous or egregious acts, policies, or practices" that deny fair
trade to U.S. products.1 4 3 If a country on this Watch List is not a member state of the WTO,
the U.S. government can initiate unilateral trade sanctions.'n Countries in agreement with
the World Trade Organization, or other international unions like the North American Free
Trade Agreement, may have dispute settlement proceedings initiated by the U.S. government
against them.1 4 5 As of the 2014 301 Special Report, 27 countries are on the Watch List, and
10 countries have been listed in the Priority Watch List.1 4 6 Several countries have continually
been listed every year, including China, India, and Thailand. 147 A majority of the reason
these countries make the list is due to the issuance of compulsory licenses in emergency
situations, which are part of the flexibility of the Doha Declaration.1 4 8 Even though the U.S.
is on alert for practices against U.S. intellectual property rights, the U.S. government
49
continues to reaffirm its commitment to the Doha Declaration and promote public health.1
B. U.S. Government and Domestic Pharmaceuticals
Besides agreements with international organizations, the United States government
has enacted reforms to bridge the gap between national public health and intellectual property
rights.' 50 The Orphan Drug Act and the Hatch-Waxman Act, passed in 1983 and 1984
respectively, were designed to influence the pharmaceutical industry to join the campaign for
promoting public health.' 5' The Hatch-Waxman Act, formally known as the Drug Price
Competition and Patent Term Restoration Act, was an amendment to the Federal Food, Drug,
and Cosmetic Act.1 5 2 This law, forefronted by Congressmen Henry Waxman and Orrin
B.G. FROMAN, THE U.S. TRADE REPRESENTATIVE, 2014 SPECIAL 301 REPORT 59 (2014)
[hereinafter Froman] (issuing the Special 301 Report for the 2014 year on behalf of the U.S. Executive Office);
19 U.S.C. § 2242, supra note 140.
142 MICHAEL

143 Froman, supra note 142.
14 John T. Masterson, Enforcement of Trademarks and Copyrights under the WTO Agreement on TradeRelated Aspects of Intellectual Property Rights, in INTERNATIONAL TRADEMARKS AND MANAGEMENT 1, 20

(John T. Masterson ed., Am. Bar Ass'n Publ'g 2004).
145 Id. at 7.
146

Froman, supra note 142.

'4

Id.

148

Pier DeRoo, "Public Non-Commercial Use" Compulsory Licensing for Pharmaceutical Drugs in
Government Health Care Programs,32 MICH. J. INT'L L. 347, 358 (2011).
149 H.R. Res. 525, 1 10th Cong. (2007) (stating United States reaffirming its commitments to the 2001 Doha
Declaration on the TRIPS Agreement).
s See generally, Public Health, Innovation and Intellectual Property Rights: Report of the Commission on
Intellectual Property Rights, Innovation and Public Health, WORLD HEALTH ORGANIZATION,
http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf
''
See generally Wendy H. Schacht & John R. Thomas, The "Hatch-Waxman" Act: Selected Patent-Related
Issues, CONG. RESEARCH SERVICE (Apr. 1, 2002), http://congressionairesearch.com/RL31379/document.php?
study-The+Hatch- Waxman+Act+Selected+Patent-Related+Issues
(discussing the Hatch-Waxman Act);
Enrique Seoane-Vazquez et al., Incentives for Orphan Drug Research and Development in the United States,
ORPHANET JOURNAL OF RARE DISEASES (Dec. 16, 2008), http://www.ojrd.com/content/3/l/33 (discussing the
Orphan Drug Act); Anton Leis Garcia, Is the Copy Better than the Original? The Regulation of Orphan Drugs:
DASH
HARVARD
(Mar.
2004)
Comparative
Perspective,
a
US-EU

http://dash.harvard.edu/bitstream/handle/l/8852101/OrphanDrugsRTF.pdf?sequence=l.
152 Schacht et al., supra note 151.
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Hatch, sought to regulate the manufacturing of generic drugs and encourage the
pharmaceutical industry to produce these generic drugs. 153 It brought about significant
changes to patent laws, specifically pharmaceutical patents. 154 These types of patents not
only need to be approved by the USPTO, but must also attain market approval from the Food
and Drug Administration (FDA), which promotes public health by supervising the safety of
food and drug products. 5 This FDA approval typically causes delays in the patent term for
the pharmaceutical, but the Hatch-Waxman Act extends the term life for these patents to
reflect regulatory delays. 156 Another aspect of this act that caused significant patent law
change (as well as controversy) is known as paragraph IV certification.'
Under this certification, when a generic drug product seeks to enter the market, the
generic drug company must file an Abbreviated New Drug Application (ANDA) to gain
approval from the FDA. ' This certification process has two possible outcomes: either the
FDA approves the generic drug once the last patent on the brand name drug expires, or the
generic drug does not infringe the brand name drug and those patents are not enforceable
against the generic product. 5 9 Once the generic product company files an ANDA and
receives certification, the brand drug company is notified and has 45 days to file a patent
infringement suit against the generic company. 1o If a suit is filed, the FDA cannot approve
the generic ANDA until the suit is over, or until 30 months lapses, whichever comes first. 161
Filing an ANDA is still worthwhile for the generic company, because if the company is first
to file the application and wins the infringement lawsuit, that generic drug product has market
exclusivity for 180 days.1 6 2 This allows for the generic product to mark prices well below the
comparable brand name drug, acquire market share from the brand drug, and make a profit
before other generic drugs enter the market, especially if the branded product is a
"blockbuster" drug and in high demand.
Like the Hatch-Waxman Act, the Orphan Drug Act also amended the Federal Food,
Drug, and Cosmetic Act.164 It aimed to promote public health while protecting patent rights
at the same time. 1s An orphan drug is a pharmaceutical developed specifically for the
16 6
The
purpose of treating orphan diseases, which are rare illnesses and medical conditions.
Rare Disease Act of 2002 defines these orphan diseases as "any disease or condition that

1s3

Id.

154

Id.

. ParagraphIV Drug Product Applications: Generic Drug Patent Challenge Notifications, U.S. FOOD AND
DRUG ADMINISTRATION (Last updated March 27, 2014), http://www.fda.gov/drugs/developmentapproval
process/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/
ucml47166.htm.
156 Schacht et al., supra note 15
1.
15 Paragraph Four Explained, PARRY ASHFORD PUBLICATIONS (Last visited January 27, 2015),
http://www.paragraphfour.com/explainedi/process.html.
1ss Id.
15s

Id.

16 Id.
161 Id.
162 Id.

Paragraph Four Explained, supra note 157.
16 Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049, 2049 (1983).
65 id.
163

16 Sharma Aarti et al., Orphan Drug: Development Trends and Strategies, 2 J. PHARM. AND BIOALLIED SC.
290, 290-99 (2010).
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affects less than 200,000 people in the United States," which is about I in every 150,000
These are the type of illnesses that doctors may encounter only once a year. 168In
people.
the U.S. some of these diseases include Crohn's disease, cystic fibrosis, and tuberculosis. 169
What might be considered a rare disease in the United States might not be in other
countries."o For instance, tuberculosis is much more prevalent in developing countries like
India and China.' 7 ' So an orphan drug may not only treat rare diseases, but also those
diseases that would not be worth the time and effort for U.S. pharmaceutical companies to
develop.' 72 Developing new medicine can be costly and time consuming. 7 3 Because
pharmaceutical companies can predict low return on manufacturing drugs for an orphan
disease, they are less likely to spend the cost to develop them. 174 This causes many diseases
to be ignored, which, although they might be considered rare, still affect thousands of people
in the U.S.
Due to the poor economic potential of these drugs for the pharma industry,
government
intervention
was
necessary.
The Orphan Drug Act aims to facilitate the research and development of orphan
drugs through financial incentives. 7 7
Motivating factors for promoting this type of
investment include tax breaks, increased patent protection and property marketing rights,
research subsidies, and government-run programs to engage research and development. 178
The government established a 50% tax credit for expenses used during clinical and
experimental trials for pharmaceutical testing, seven-year market exclusivity for the product,
and about 15 grants awarded annually to researchers and companies. 17 9 Over the past three
decades, the Orphan Drug Act has largely been a success. 8o As of 2010, more than 200 rare
diseases have become treatable, and over 350 drugs and 2,000 drug compounds have been
approved by the FDA.'"' The FDA even created its own department, called the Office of
Orphan Product Development, to administer this development.1 82
This devotion to
developing orphan drugs and fighting rare diseases has sparked a global effort towards the
manufacturing of these drugs as well. 183 Countries like Japan, Canada, and a host of European

16

H.R. 4013, 107th Cong. (2002).

68 Aarti et al., supra note 166, at 290.
169 Aarti et al., supra note 166.
17o

Id.

"' See
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FoUND.,

http://kff.org/global-indicator/tuberculosis-hbcs/ (last updated 2014).
172 Aarti et al., supra note 166, at 290.
173 Id; Seoane-Vazquez et al., supra note 151.
174 Seoane-Vazquez et al., supra note 151.
's

Aarti et al., supra note 166, at 290.

176 Seoane-Vazquez, supra note 15 1.
'n

Id.
178 Id.

17 Id.
80 Mia Bums, Report Projects Global Orphan Drug Market to Tap $112 Billion in 2017, DRUGS.COM (2013),

http://www.drugs.com/news/report-projects-global-orphan-market-tap-I
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181 Seoane-Vazquez, supra note 151, at 21.
182 Id.
183 Burns, supra note 180.
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nations have joined the movement too.1 84 It is predicted that the global orphan drug market
will reach $112 billion by 2017, and $120 billion by 2018, with the U.S. accounting for a little
more than half of the market. 185
This movement toward increasing research and development affects the private
sector as well as federal agencies.'1 6 Even though private industry based funds more than
double the amount of government based funds, the private companies still benefit directly
from the government tax breaks associated with research and development.'8 Companies
also offer their own internal incentives to encourage their employees to participate in the
invention process.
For instance, they may propose their own system of financial
incentives, like a salary bonus or a patent royalty. 1
A company can also reward an
employee/inventor with internal awards and recognition.'90 One first-hand, personal account
of a patent agent's experience working for a company with such incentives comes from Russ
Krajec, an attorney and engineer working in Colorado. '9 Before practicing as a solo
attorney, Mr. Krajec worked as an engineer for Hewlett Packard, which operated its own
patent incentive programs.192 Mr. Krajec has discussed his experience working under one of
these programs, which can offer up to $250 for submitting a patent disclosure to the USPTO,
and up to $5000 when a patent issues.193 He has submitted about 15 disclosures himself, with
about ten issuing has independent patents.1 9 4 The patent incentive programs were good
motivational tools, he claims, but they would also lead to some controversy. 195 For instance,
other employees would claim they were co-inventors on certain inventions they had no
business being included in.196 So while the incentive programs may cause tense competition
intra-company, they also motivate employees, like Mr. Krajec, to work harder in research and
development.' 97 This shows how the Hatch-Waxman Act, the Orphan Drug Act, and the
effects they have had in the U.S. are good illustrations of possible systems that developing
countries can implement to promote public health.

Emmanuelle Lecomte, Development of InternationalOrphan Drug Policies, EUROPEAN CONFERENCE ON
RARE
DISEASES
(2014),
http://www.rare-diseases.eu/wp-content/uploads/2014/05/0401 Emmanuelle_
LECOMTE-BRISSET.pdf.
185 Bums, supra note 180; Neeraj Chawla, Global Orphan Drug Market to Reach US$ 120 Billion by 2018, PR
NEWSWIRE (Feb. 7, 2014), http://www.prnewswire.com/news-releases/global-orphan-drug-market-to-reach-us120-billion-by-2018-244195511 .html.
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IV. CHINA'S MOVEMENT TO IMPROVE PUBLIC HEALTH
A. China's Healthcare Reform
China is currently undergoing a major healthcare system overhaul." For decades,
there has been a staggering difference in the quality, accessibility, and affordability of
healthcare available between rural and urban parts of China.'99 Not only the disparity
between the regions, but the overall inflated prices of drugs, and the denial of care to those
without the ability to afford it no matter what part of China they were from, has sparked civil
unrest. 2 0 0 Protests and even acts of violence have marred Chinese society throughout the
country.201 In 2009, the Chinese government finally released a two-tiered plan for a reform
framework.202 The more long-term plan is called the Framework Plan, or the State Council's
Opinions on Deepening Healthcare System Reform, and aims to be established through the
year 2020.203 The Chinese Ministry of Health, now integrated into the National Health and
Family Planning Commission in 2013 as part of the reforms, implemented a more detailed
roadmap: the Ministry of Health's Implementation Plan for Immediate Priorities in Healthcare
System Reform, or the Implementation Plan for short. 2 0 4 This plan was relatively short-term
and aimed to be instituted from 2009-2011.205 As a whole, the reform policy sought to cover
five priority areas: providing universal coverage of basic medical insurance and increasing the
value of the insurance coverage program benefits; establishing an essential drug system that
would implement increased use in generic drugs and ensure a safe supply of medicine;
upgrading the infrastructure for primary health care; creating greater equality between rural
and urban public health access; and initiating a pilot reform policy for public hospitals, as
206
well as policies to facilitate private investment for hospitals.
China's government initially pledged to invest $124 billion into the healthcare
reform, but as of early 2014, the total had already surpassed $371 billion.20 7 This large
amount of spending, however, has brought positive outcomes.208 For instance, rural insurance
coverage has reached its goal of a 90% coverage rate, and about 400 million urban citizens

'9
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are enrolled in an insurance program. 20 9 In terms of private hospitals, the Ministry of Health
sought an increase in private investments from 8% in 2012 to 20% by 2015.20 As of 2014,
the transaction to increase the amount of private investors in hospital management had driven
in over $1.7 billion of capital. 2 1 ' Despite all of this, there is still much more ground for
212
China's health department to cover.
For one thing, even with all the money the
government spent, only one-third goes towards patients and consumers, while two-thirds is
for healthcare providers (which may seem like a good thing, but less than 10% of the
213
There are still about 300 million
government's contributions reach public hospitals).
people living in urban areas without medical insurance coverage, and regardless of where
people live, the price of medicine is still inaccessibly high and overcrowded hospitals deny
214
care to the more indigent.
B. China's Pharmaceutical Patent Industry
Patent laws in the People's Republic of China are quite similar to those in the
United States.2lS China follows the Patent Cooperation Treaty, joined the World Trade
216
China offers both
Organization in 2001, and is a member state of the TRIPS Agreement.
211
utility and design patents and requires that patents are novel and incorporate prior art.
China's patent review system, however, does not require substantive examination as the
USPTO does; therefore, it is easier to acquire patent rights in China. 2 18 The patent
department does not have the necessary amount of patent examiners, nor the financial
21 9
Even
resources to hire enough, to conduct thorough examinations of patent applications.
though patent rights may be more easily granted in China, and patent protection lasts only 10
220
Actually, it is
years instead of 20, this does not mean that patents are easier to invalidate.
quite the contrary, since China has implemented a discretionary review policy, which
provides a more substantive examination of particular applications. 22 The Chinese system
also enforces a maximum of two references to be used in an obviousness rejection of a patent
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application.222 Companies and independent investors in China will continue to pursue patent
protection rights, because even though the examination process is quick and cheap, the
validity of their patents are still strong. 223
As China uhdergoes its healthcare reform, and the government tries to make
medicine and drugs more affordable and accessible, there will be a larger push towards
224
generic pharmaceuticals.
With a high demand for low cost drugs, companies in the big
pharma industry that are issued dozens of patents on pharmaceuticals will be the most
affected by this.225 Large drug distributors in China, like SinoPharm Group and Shanghai
Pharmaceutical Co., will not be able to handle this type of thin margin market, nor would they
be willing to, especially when they have patent protection for the brand named medicine.226
As a result of this reform, researchers will be more inclined to invest their time and money
researching and developing drugs for the masses.227 With many people receiving insurance
program coverage, the economic potential for investing in popular, or "blockbuster," drugs
will be worthwhile. 22
This, unfortunately, will leave those affected by rare medical
229
conditions and orphan diseases relatively in the dark.
Companies are less likely to devote
resources to developing medicine that would only be used by a small percentage of the
230

-

population.
The proposal introduced in the beginning of this note would substantially aid the
Chinese government in overcoming many dilemmas they face amidst the healthcare reform.
The government is developing certain measures and outlines, however, adopting two
important, if not the most important, amendments to the U.S. Food, Drug, and Cosmetic Act
the Hatch-Waxman Act and the Orphan Drug Act - would provide an already established
framework for this system. The Chinese government has published a National Essential Drug
List to guide prices of the drug market, and has made the push towards a more generic drug
market, which at the beginning of 2015 neared almost $82 billion. 2 3 1 China, however, has
been accused of corruption, impropriety, and increased hostility towards foreign companies,
especially in the big pharma industry. 23 2 This is evidenced by one of the largest generic drug
manufacturers, Actavis, leaving the Chinese drug market. 23 3 China has also established its
own definition of rare and orphan diseases and has attempted to create incentives for orphan
drugs through procedures such as the New Drug Approval Regulation, the Drug Registration
Regulation, and the Special Review and Approval Procedures for Drug Registration.23 4 These
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have established guidelines and criteria for accelerated approval of orphan drugs, but
"detailed rules have yet to be implemented and further incentives have not been proposed."2 3 5
According to a 2014 study by the European Committee of Rare Diseases, China has
established neither an "orphan drug program nor special funding for orphan drug research." 2 3 6
Other players in the Asian drug market, however, like Japan and South Korea, have
237
established their own orphan drug acts and regulations.
With all of this still looming as China enters the sixth year of its healthcare reform,
the joint implementation of the Hatch-Waxman Act and the Orphan Drug Act would create
the solid foundation the reform needs to combat these issues.238 The Hatch-Waxman Act
would help establish a modem system for generic drug manufacturing that would not only
protect intellectual property rights, but also provide a gateway that encourages the production
of generic drugs in the pharmaceutical industry.239 The Orphan Drug Act would establish
funding and incentives for private sector companies to devote resources towards research and
development of orphan drugs.240 These two acts have been successful and influential in the
United States for over thirty years.21 Together, their implementation would protect
pharmaceutical patent rights while also improving national and international public health,
helping Chinese healthcare reform become that much more successful.
V. CONCLUSION
242

As discussed before, the United States and China have similar patent systems.
They also have similar drug administration systems, which, through implementation of this
proposal, would make the transition of the drug system feasible and reasonable. 2 43 The
Chinese government created the State Food and Drug Administration (SFDA), "influenced by
the U.S. model," and passed the Drug Administration Law in 2001.244 This established a
245
Just as U.S. drug makers have to seek
regulatory system for drug approval and registration.
authorization from the FDA, the SFDA also has to approve new drugs for market production
and availability.246 Like the U.S. Department of Health and Human Services, the Ministry of
Health of the People's Republic of China oversees the laws, policies, and regulations related
to public health, and would be the organization to undertake the implementation of the
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proposal.247 During the next phase of China's healthcare reform, the long-term Framework
Plan, the Ministry of Health would be the governmental branch to implement the system
frameworks of the Hatch-Waxman Act and the Orphan Drug Act in order to institute the new
248
system.
drug
essential
The world that once made it difficult for HIV/AIDS victims to receive the proper
medicine, and turned its head on those suffering from rare medical conditions, is now making
efforts to strive towards a more public-health conscientious global community. 24 9 With
essential medicine more readily accessible and more time and money being invested in
developing orphan drugs, the world may become a place where no one is denied access to
necessary medicine.25 0 China may follow in these footsteps and become a place where a
25
father does not have to abandon his baby in order for it to receive proper medical care. 1
China can become a place where every child has access to the necessary care and
pharmaceuticals. 252

Ministry of Health, THE STATE COUNCIL OF THE PEOPLE'S REPUBLIC
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